Home/Filings/4/0001209191-20-005794
4//SEC Filing

Richardson Joshua 4

Accession 0001209191-20-005794

CIK 0001290149other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 4:58 PM ET

Size

9.4 KB

Accession

0001209191-20-005794

Insider Transaction Report

Form 4
Period: 2020-01-29
Richardson Joshua
Director10% Owner
Transactions
  • Conversion

    Series A Convertible Voting Preferred Stock

    2020-01-2919,5000 total(indirect: By Longitude Venture Partners III, L.P.)
    Common Stock (1,477,320 underlying)
  • Conversion

    Common Stock

    2020-01-29+1,477,3201,477,320 total(indirect: By Longitude Venture Partners III, L.P.)
Footnotes (4)
  • [F1]On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split.
  • [F2]Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date.
  • [F3]Longitude Capital Partners III, LLC ("LCP III") is the general partner of Longitude Venture Partners III, L.P. ("LVP III") and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and the Reporting Person (a member of the Issuer's board of directors), are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
  • [F4]Consists of 19,500 shares of Series A Preferred Stock held by LVP III which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split.

Issuer

Sierra Oncology, Inc.

CIK 0001290149

Entity typeother

Related Parties

1
  • filerCIK 0001793762

Filing Metadata

Form type
4
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:58 PM ET
Size
9.4 KB